129
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Polycythemia vera: can we do better?

, MBBS BSc(Hons) MRCP & , DM FRCP FRCPath
Pages 687-689 | Published online: 15 Mar 2013

Bibliography

  • James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
  • Scott LM, Tong W, Levine RL, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356(5):459-68
  • Cassinat B, Laguillier C, Gardin C, Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 2008;22(2):452-3
  • Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005;129(5):701-5
  • McMullin MF, Bareford D, Campbell P, Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130(2):174-95
  • Wasserman LR, Balcerzak SP, Berk PD, Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians 1981;94:30-8
  • Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;2(8102):1219-22
  • Thomas DJ, Marshall J, Russell RW, Effect of haematocrit on cerebral blood-flow in man. Lancet 1977;2(8045):941-3
  • Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002;116(2):243-54
  • Hensley B, Geyer H, Mesa R. Polycythaemia vera: current pharmacotherapy and future directions. Exp Opin Pharm 2013;14(5):609-617
  • Marchioli R, Finazzi G, Specchia G, Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22-33
  • Spivak JL. Polycythemia vera, the hematocrit, and blood-volume physiology. N Engl J Med 2013;368(1):76-8
  • Barosi G, Birgegard G, Finazzi G, Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113(20):4829-33
  • Barosi G, Tefferi A, Barbui T. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia 2012;26(5):1148-9
  • Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117(18):4706-15

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.